Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

stevenryl86 Dec. 14 at 3:51 AM

$GRI any upcoming catalyst?

1 · Reply

commanche Dec. 14 at 2:32 AM

$GRI i am not in this anymore. Will only revisit after R/S. I got a clearer idea on this company/management after this past few weeks. Good luck to all whos still holding

1 · Reply

Mahdinur Dec. 13 at 10:20 PM

$GRI And because offering is closed, any RS will slush the count of the new shareholders who took received issuing of new shares. Plus cannot dilute before 60 days Plus pre funded warrants not to be striked until S1 i believe They previously had RS because no catalyst. They now have phase 2a

1 · Reply

Mahdinur Dec. 13 at 9:53 PM

$GRI

1 · Reply

mendez628 Dec. 13 at 7:32 PM

$GRI here’s to being optimistic..

0 · Reply

Peaceouty Dec. 13 at 5:31 PM

$GRI Shareholders own all the shares in the company, yet have no control… how does that work? The dude is running it as a private company. Surely there’s a way to sue them. I know it’s a bio, but clearly they’re doing nothing to protect the shareholders.

0 · Reply

martinisax Dec. 13 at 2:31 PM

$GRI thanks CEO because I'm loss 75% in about 2 month

1 · Reply

dButterz Dec. 12 at 11:30 PM

$GRI somebody trying to load the boat at .51🤓🤓🤓

1 · Reply

dButterz Dec. 12 at 11:27 PM

$GRI hey look at the bright side everyone 🤣🤣🤣 we finished green today🤷‍♂️

0 · Reply

mendez628 Dec. 12 at 11:16 PM

$GRI got absolutely decimated this week, but I have hope we can recoup some of our losses. I don’t anticipate this hitting 2.00 again for a very long time, but if I get even remotely close, I’m gone and holding the L to move on. Good luck, ya’ll. This has been a brutal week.

1 · Reply

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 2 days ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 10, 2025, 4:05 PM EST - 3 days ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 3 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Aug 14, 2025, 9:15 AM EDT - 4 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 4 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 22, 2025, 8:45 AM EDT - 5 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:45 AM EDT - 5 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 6 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 9:15 AM EDT - 7 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 16, 2025, 9:15 AM EDT - 7 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 15, 2025, 8:35 AM EDT - 7 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 8, 2025, 8:45 AM EDT - 7 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 7 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 8 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 9 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 9 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:07 AM EDT - 9 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Mar 31, 2025, 8:00 AM EDT - 9 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 18, 2025, 9:05 AM EDT - 9 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 9 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 11, 2025, 8:35 AM EDT - 9 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 4:05 PM EST - 10 months ago

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 9:00 AM EST - 10 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

stevenryl86 Dec. 14 at 3:51 AM

$GRI any upcoming catalyst?

1 · Reply

commanche Dec. 14 at 2:32 AM

$GRI i am not in this anymore. Will only revisit after R/S. I got a clearer idea on this company/management after this past few weeks. Good luck to all whos still holding

1 · Reply

Mahdinur Dec. 13 at 10:20 PM

1 · Reply

Mahdinur Dec. 13 at 9:53 PM

$GRI

1 · Reply

mendez628 Dec. 13 at 7:32 PM

$GRI here’s to being optimistic..

0 · Reply

Peaceouty Dec. 13 at 5:31 PM

0 · Reply

martinisax Dec. 13 at 2:31 PM

$GRI thanks CEO because I'm loss 75% in about 2 month

1 · Reply

dButterz Dec. 12 at 11:30 PM

$GRI somebody trying to load the boat at .51🤓🤓🤓

1 · Reply

dButterz Dec. 12 at 11:27 PM

$GRI hey look at the bright side everyone 🤣🤣🤣 we finished green today🤷‍♂️

0 · Reply

mendez628 Dec. 12 at 11:16 PM

1 · Reply

Caveman25 Dec. 12 at 10:33 PM

$GRI Insider ownership is reported to be very low, around 0.0144% of the total shares, or approximately 471 shares held by individual insiders. Insider Trading Activity: Recent data suggests no insider buying or selling activity (zero buys and zero sells) over the prior 3 and 12 months. Total Insiders: There is a count of 7 total insiders. If I was a GRI BIO insider I would definitely buy some stocks at this price.

0 · Reply

elkhro Dec. 12 at 10:13 PM

$GRI Next week

1 · Reply

Caveman25 Dec. 12 at 10:11 PM

$GRI No dead cat bounce yet 😂

1 · Reply

AtlasOG Dec. 12 at 10:11 PM

$GRI back to .80+

0 · Reply

elkhro Dec. 12 at 10:08 PM

$GRI GRI just locked in $8M cash + another potential $8M if warrants at $0.75 get exercised. That’s a full $16M runway potential without any new dilution. Offering is closed. Company is cash-secure into late 2026, and dilution is legally frozen for 60 days + no variable-rate deals for 12 months. Now the stock is free to move. If we reclaim $0.75, warrants get exercised and GRI doubles its cash position. Biggest risk short-term is gone. Now we watch the next catalysts

0 · Reply

Draindrop Dec. 12 at 10:01 PM

$GRI all up from here. https://finance.yahoo.com/news/gri-bio-announces-closing-8-210500307.html

1 · Reply

elkhro Dec. 12 at 9:53 PM

$GRI You do know that companies this size uses external labs to perform their tests? But back to your earlier post. I would invest in a company with 4 employees. Would you?

1 · Reply

Caveman25 Dec. 12 at 9:50 PM

$GRI can you find me one image of the company in a lab or hospital. I couldn't find any?

0 · Reply

elkhro Dec. 12 at 9:42 PM

$GRI yes I do. Do you?

0 · Reply

elkhro Dec. 12 at 9:41 PM

$GRI The offering is closed as planned • Company raised approx $6.7M net • Fully funded into Q4 2026 • No toxic financing, no variable-rate deals allowed for 12 months • 60-day lockout on new issuances → no immediate dilution • Majority of the raise is pre-funded warrants, which cannot be borrowed → shorts are in trouble • Borrow fee is over 360% 🤯 Honestly, this is one of the cleanest microcap offerings in a long time. GRI now has runway, zero toxic overhang, and clinical data already showing meaningful signals.

1 · Reply

Caveman25 Dec. 12 at 9:36 PM

$GRI I love the movie reference 😂

1 · Reply

MoonDog711 Dec. 12 at 9:32 PM

$GRI

0 · Reply

Market Cap	1.73M
Revenue (ttm)	0.00
Net Income (ttm)	-8.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,516,700
Avg Vol	601,590
Day's Range	N/A - N/A
Shares Out	3.27M
Stochastic %K	2%
Beta	-1.48
Analysts	Sell
Price Target	$23.00